Matt Church

502 total citations · 1 hit paper
5 papers, 350 citations indexed

About

Matt Church is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Matt Church has authored 5 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Oncology, 2 papers in Pulmonary and Respiratory Medicine and 2 papers in Cancer Research. Recurrent topics in Matt Church's work include Cancer Genomics and Diagnostics (2 papers), Pancreatic and Hepatic Oncology Research (1 paper) and Advanced Biosensing Techniques and Applications (1 paper). Matt Church is often cited by papers focused on Cancer Genomics and Diagnostics (2 papers), Pancreatic and Hepatic Oncology Research (1 paper) and Advanced Biosensing Techniques and Applications (1 paper). Matt Church collaborates with scholars based in United Kingdom, Spain and United States. Matt Church's co-authors include Dominic G. Rothwell, Caroline Dive, Natalie Cook, Ann Tivey, Nils Daulaire, M. R. Pandey, Robin Houston, Thérèse A. Stukel, Louise Carter and Fiona Blackhall and has published in prestigious journals such as Annals of Oncology, Nature Reviews Clinical Oncology and Cells.

In The Last Decade

Matt Church

5 papers receiving 333 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating tumour DNA — looking beyond the blood

2022 194 citations Ann Tivey, Matt Church et al. Nature Reviews Clinical Oncology profile →

Peers

Countries citing papers authored by Matt Church

Since Specialization

Citations

This map shows the geographic impact of Matt Church's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matt Church with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matt Church more than expected).

Fields of papers citing papers by Matt Church

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matt Church. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matt Church. The network helps show where Matt Church may publish in the future.

Co-authorship network of co-authors of Matt Church

This figure shows the co-authorship network connecting the top 25 collaborators of Matt Church. A scholar is included among the top collaborators of Matt Church based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matt Church. Matt Church is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

#	Work	Indexed citations
1	420P An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples 2024 ·Annals of Oncology ·Sarah Statt, (unknown), Matt Church, Jeffrey L. Myers, H. H. Dale, (unknown), Kevin Kelnar, Benjamin P. Haynes	1
2	Circulating tumour DNA — looking beyond the blood breakdown → 2022 ·Nature Reviews Clinical Oncology ·Ann Tivey, Matt Church, Dominic G. Rothwell, Caroline Dive, Natalie Cook	194
3	927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients 2020 ·Annals of Oncology ·Martin Förster, Enriqueta Felip, Bernard Doger, (unknown), Enric Carcereny, (unknown), Matt Church, Julio A. Peguero, Patricia Roxburgh, Frédéric Triebel	7
4	Liquid Biopsy in Small Cell Lung Cancer—A Route to Improved Clinical Care? 2020 ·Cells ·Matt Church, Louise Carter, Fiona Blackhall	5
5	Childhood mortality after a high dose of vitamin A in a high risk population. 1992 ·BMJ ·Nils Daulaire, (unknown), Robin Houston, Matt Church, Thérèse A. Stukel, M. R. Pandey	143

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact